CREATE Medicines closed a $122 million Series B financing to advance its in vivo CAR-T platform across autoimmune disease and oncology. The company’s mRNA-LNP approach programs T cells, NK cells, and myeloid cells inside the body, aiming for repeat-dose and off-the-shelf potential without the logistics of traditional ex vivo CAR-T manufacturing. CREATE’s lead autoimmune program, CRT-402, is CD19-targeted and has shown deep, durable B-cell depletion in non-human primates. In oncology, the company reported early responses for its hepatocellular carcinoma program MT-303. It says it has dosed more than 50 patients across clinical programs to date.